Letters Antipsychotics in dementia

Licensed indication for risperidone in dementia

BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g7337 (Published 10 December 2014) Cite this as: BMJ 2014;349:g7337
  1. David Phizackerley, deputy editor
  1. 1Drug and Therapeutics Bulletin, BMJ Evidence Centre, BMA House, London WC1H 9JR, UK
  1. dphizackerley{at}bmj.com

When referring to the licensed indication for risperidone, Corbett and colleagues state: “In Europe, only risperidone is currently licensed for use in dementia and only for up to six weeks in …

View Full Text

Log in

Log in through your institution


* For online subscription